Open Label, Single Arm, Phase II Study Using R-COMP in Elderly Patients With Aggressive NHL.
Recruitment status was Active, not recruiting
To evaluate the safety and efficacy of R-COMP in elderly patients with advanced aggressive NHL. Myocet (non-pegylated liposomal doxorubicin) replaces conventional doxorubicin in the R-CHOP regimen.
Aggressive Non-Hodgkin's Lymphoma in the Elderly.
Drug: Cyclophosphamide, oncovin, myocet, prednisone & rituximab (R-COMP)
|Study Design:||Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Cyclophosphamide, Oncovin, Myocet, Prednisone and Rituximab (R-COMP) in the Treatment of Elderly Patients With Aggressive NHL.|
- Response rate
|Study Start Date:||October 2002|
To evaluate the duration of remission, disease free survival and 2-year survival of R-COMP in first line therapy of elderly patients with advanced aggressive NHL.
To evaluate the tolerability of R-COMP in first line therapy of elderly patients with advanced aggressive NHL.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00244127
|Universita Degli Studi Di Modena AZ Ospedaliere Policlinico|
|Modena, Italy, 41100|
|Leicester, United Kingdom|
|Principal Investigator:||Massimo Federico||Universita Degli Studi di Modena|